{"product_id":"luciaxi-axitinib","title":"LuciAxi (Axitinib)","description":"\u003ch2\u003eAbout Axitinib\u003c\/h2\u003e\u003cp\u003eAxitinib  is a small molecule tyrosine kinase inhibitor. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models\u003csup id=\"cite_ref-4\" class=\"reference\"\u003e\u003c\/sup\u003e and has shown partial responses in clinical trials with renal cell carcinoma (RCC)\u003cspan style=\"font-size: 13.3333px\"\u003e  \u003c\/span\u003eand several other tumour types.\u003csup id=\"cite_ref-6\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch3\u003eRenal Cell Carcinoma\u003c\/h3\u003e\u003ch4\u003eMonotherapy\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated for advanced renal cell carcinoma (RCC) in patients who failed 1 prior systemic therapy\u003c\/li\u003e\n\u003cli\u003e5 mg PO BID initially\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCombination therapy with avelumab\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with avelumab for first-line treatment of advanced RCC\u003c\/li\u003e\n\u003cli\u003eAxitinib 5 mg PO BID, plus\u003c\/li\u003e\n\u003cli\u003eAvelumab 800 mg IV q2Weeks\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eDuring combination therapy with avelumab, consider escalating dose of axitinib above 5 mg\/dose in 2-week intervals or longer\u003c\/li\u003e\n\u003cli\u003eRefer the prescribing information of avelumab for dosing information\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCombination therapy with pembrolizumab\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with pembrolizumab for first-line treatment of advanced RCC\u003c\/li\u003e\n\u003cli\u003eAxitinib 5 mg PO BID, plus\u003c\/li\u003e\n\u003cli\u003ePembrolizumab 200 mg IV q3Weeks or 400 mg IV q6Weeks\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eDuring combination therapy with pembrolizumab, consider escalating dose of axitinib above 5 mg\/dose in 6-week intervals or longer\u003c\/li\u003e\n\u003cli\u003eRefer the prescribing information of pembrolizumab for dosing information\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954785323,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0927.jpg?v=1787022228","url":"https:\/\/xomeds.com\/products\/luciaxi-axitinib","provider":"XOMEDS","version":"1.0","type":"link"}